Edgewise’s stock jumps 50% on the back of safety data for …

Dec 27, 2024 · The early data had pushed the company’s shares up 55% to $29.50 by the close of trading Thursday. Should EDG-7500 eventually make it to market, the drug will find itself …

50%
OFF

Edgewise’s Stock Jumps 50% On The Back Of Safety Data For …

2 weeks from now

Dec 27, 2024 · The early data had pushed the company’s shares up 55% to $29.50 by the close of trading Thursday. Should EDG-7500 eventually make it to market, the drug will find itself …

biotech-insider.com

50%
OFF

Edgewise's Stock Jumps 50% On The Back Of Safety Data For …

2 weeks from now

Dec 27, 2024 · Edgewise Therapeutics’ hypertrophic cardiomyopathy (HCM) asset has started off with a bang after early safety data sent the company’s shares soaring. Edgewise tested its …

biotech-today.com

50%
OFF

Edgewise Therapeutics Sees 50% Stock Surge Following Positive …

2 weeks from now

Sep 20, 2024 · Clinical Data: The positive Phase 1 data, although from a small 7-patient dataset, significantly impacts Edgewise's valuation and highlights the importance of early-stage assets. …

talk.bio

50%
OFF

Edgewise's Stock Soars 50% After Heart Disease Drug Safety Data

2 weeks from now

Edgewise Therapeutics has made a significant entrance into the hypertrophic cardiomyopathy (HCM) treatment space, as early safety data for its drug candidate, EDG-7500, has …

patsnap.com

50%
OFF

Why Edgewise Therapeutics Stock Is Up 50% On Thursday - Yahoo …

2 weeks from now

Sep 19, 2024 · Shares of biopharma outfit Edgewise Therapeutics (NASDAQ: EWTX) soared more than 50% today, reaching a three-year high following an update on the clinical testing of …

yahoo.com

50%
OFF

Edgewise's Stock Jumps 50% On The Back Of Safety Data For …

2 weeks from now

Edgewise Therapeutics's hypertrophic cardiomyopathy (HCM) asset has started off with a bang after early safety data sent the company’s shares soari...

biotech-now.co.uk

7%
OFF

Edgewise Therapeutics Skyrockets After Hitting A Slam Dunk In ...

2 weeks from now

Sep 19, 2024 · Edgewise Therapeutics stock soared 54.7%, closing at 29.50. Shares opened at their highest point since June 2021. ... "We do think repeat-dosing data will better inform on …

investors.com

50%
OFF

Edgewise's Stock Jumps 50% On The Back Of Safety Data For …

2 weeks from now

Sep 20, 2024 · Edgewise's stock jumps 50% on the back of safety data for potential heart disease rival to Camzyos zbecker Thu, 09/19/2024 - 17:26 ... Biotech News; Post a Biotech Job; Close …

biotechjobs.io

332%
OFF

Edgewise Stock Up 332%: Analysts Believe It's Not Too Late

2 weeks from now

Sep 25, 2024 · Edgewise’s Muscular Dystrophy Treatments Have Large Market Than Others. Edgewise currently has two drugs that are driving the company. They are Sevasemten and …

marketbeat.com

50%
OFF

Edgewise's Skeletal Myosin Inhibitor Reduces Biomarker In Phase 2 ...

2 weeks from now

Dec 16, 2024 · Edgewise's stock jumps 50% on the back of safety data for potential heart disease rival to Camzyos. Investors seemed unfazed by the less clear-cut secondary endpoint data, …

fiercebiotech.com

50%
OFF

EDG-7500 - Drug Targets, Indications, Patents - Synapse - Patsnap

2 weeks from now

Nov 21, 2024 · Edgewise's stock jumps 50% on the back of safety data for potential heart disease rival to Camzyos. ... (HCM) asset has started off with a bang after early safety data sent the …

patsnap.com

FAQs about Edgewise’s stock jumps 50% on the back of safety data for … Coupon?

Is Edgewise a good stock to buy?

Sevasemten, Edgewise's lead drug, remains unchanged in its potential, with ongoing pivotal studies for Becker Muscular Dystrophy. Edgewise stock has surged over 50% today however on Phase 1 data for EDG-7500, a cardiac sarcomere modulator for hypertrophic cardiomyopathy and diastolic dysfunction. ...

Why is Edgewise stock soaring today?

Edgewise stock is soaring today, up over 50% at the time of writing. It reached a high of $29 per share, and that is a jump of over 60% since my "sell" recommendation. The jump came due to data shared from a Phase 1 study of EDG-7500. ...

When did Edgewise IPO?

Before diving into the data, to briefly recap Edgewise's history and current financials, the company completed its IPO in April 2021, which raised ~$150m at ~$15 per share. ...

Will Edgewise Therapeutics topline edg-7500 data ahead of time?

However, “we do not know if the company will topline EDG-7500 data ahead of time and subsequently present additional results at HFSA,” she added. Shares of Edgewise Therapeutics (NASDAQ:EWTX) added ~10% on Tuesday after Piper Sandler cited a potential catalyst related to the company’s experimental heart disease therapy, EDG-7500. ...

Will Edgewise Therapeutics stock hit a three-year high?

E dgewise Therapeutics stock skyrocketed — and is posed to hit a three-year high — on Thursday after a single dose of its drug improved heart function in cardiomyopathy patients. Please watch the video at Investors.com - The Cell Therapy Market Is Expected To Grow 600% Over The Next Decade. This Biotech Is Poised To Capitalize On That Wave. ...

Is Edgewise Therapeutics a sell?

I previously rated Edgewise Therapeutics a sell due to limited market potential and lack of clinical data for sevasemten. Sevasemten, Edgewise's lead drug, remains unchanged in its potential, with ongoing pivotal studies for Becker Muscular Dystrophy. ...